Gregory Renza
Stock Analyst at Truist Financial
(4.86)
# 380
Out of 5,136 analysts
885
Total ratings
52.1%
Success rate
18.7%
Average return
Main Sectors:
Stocks Rated by Gregory Renza
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CATX Perspective Therapeutics | Reiterated: Buy | $11 → $8 | $0.9238 | +765.99% | 22 | Nov 10, 2026 | |
| AGIO Agios Pharmaceuticals | Reiterated: Buy | $37 → $35 | $30.15 | +16.09% | 47 | Nov 6, 2026 | |
| GMAB Genmab | Reiterated: Buy | $67 | $51.57 | +29.92% | 10 | Nov 6, 2026 | |
| MNKD MannKind | Reiterated: Buy | $5 | $3.96 | +26.42% | 42 | Nov 6, 2026 | |
| ONC BeOne Medicines AG | Reiterated: Buy | $420 → $448 | $411.29 | +8.93% | 20 | Nov 6, 2026 | |
| AMGN Amgen | Reiterated: Hold | $380 → $398 | $462.32 | -13.91% | 45 | Nov 4, 2026 | |
| IDYA IDEAYA Biosciences | Reiterated: Buy | $57 | $30.36 | +87.75% | 35 | Nov 3, 2026 | |
| REGN Regeneron Pharmaceuticals | Reiterated: Buy | $780 → $982 | $952.40 | +3.11% | 16 | Nov 2, 2026 | |
| EXEL Exelixis | Reiterated: Hold | $54 → $60 | $67.10 | -10.58% | 38 | Oct 30, 2026 | |
| GILD Gilead Sciences | Reiterated: Buy | $158 → $181 | $167.58 | +8.01% | 19 | Oct 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $34 → $35 | $26.45 | +32.33% | 9 | Oct 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $29 → $40 | $35.40 | +12.99% | 36 | Oct 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $240 → $241 | $166.87 | +44.42% | 11 | Oct 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $34 → $33 | $14.73 | +124.03% | 28 | Oct 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $286 | $239.77 | +19.28% | 45 | Oct 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $87 → $85 | $26.80 | +217.16% | 4 | Oct 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $155 → $151 | $83.61 | +80.60% | 13 | Sep 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $3.84 | - | 29 | Sep 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $84.78 | - | 23 | Sep 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $29.80 | - | 37 | Sep 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $13.29 | - | 5 | Aug 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $3.71 | - | 18 | Aug 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $7 | $3.18 | +120.13% | 9 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $26 | $18.67 | n/a | 57 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $1.25 | n/a | 24 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $5 | $1.40 | n/a | 36 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $20 | $3.20 | n/a | 23 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $16 | $7.70 | n/a | 23 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $48 → $46 | $11.77 | n/a | 8 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $26 | $36.48 | n/a | 31 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $16 | $5.24 | n/a | 15 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 → $13 | $4.82 | n/a | 14 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $38 | $42.25 | n/a | 26 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $2,160 → $180 | $7.37 | n/a | 11 | Jun 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $20.41 | $2.05 | n/a | 23 | May 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $5 → $80 | $0.4063 | n/a | 18 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1 → $15 | $0.000001 | n/a | 14 | Nov 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $348 | $251.65 | n/a | 1 | Sep 8, 2015 |
Perspective Therapeutics
Nov 10, 2026
Reiterated: Buy
Price Target: $11 → $8
Current: $0.9238
Upside: +765.99%
Agios Pharmaceuticals
Nov 6, 2026
Reiterated: Buy
Price Target: $37 → $35
Current: $30.15
Upside: +16.09%
Genmab
Nov 6, 2026
Reiterated: Buy
Price Target: $67
Current: $51.57
Upside: +29.92%
MannKind
Nov 6, 2026
Reiterated: Buy
Price Target: $5
Current: $3.96
Upside: +26.42%
BeOne Medicines AG
Nov 6, 2026
Reiterated: Buy
Price Target: $420 → $448
Current: $411.29
Upside: +8.93%
Amgen
Nov 4, 2026
Reiterated: Hold
Price Target: $380 → $398
Current: $462.32
Upside: -13.91%
IDEAYA Biosciences
Nov 3, 2026
Reiterated: Buy
Price Target: $57
Current: $30.36
Upside: +87.75%
Regeneron Pharmaceuticals
Nov 2, 2026
Reiterated: Buy
Price Target: $780 → $982
Current: $952.40
Upside: +3.11%
Exelixis
Oct 30, 2026
Reiterated: Hold
Price Target: $54 → $60
Current: $67.10
Upside: -10.58%
Gilead Sciences
Oct 30, 2026
Reiterated: Buy
Price Target: $158 → $181
Current: $167.58
Upside: +8.01%
Oct 29, 2026
Reiterated: Buy
Price Target: $34 → $35
Current: $26.45
Upside: +32.33%
Oct 27, 2026
Reiterated: Buy
Price Target: $29 → $40
Current: $35.40
Upside: +12.99%
Oct 19, 2026
Reiterated: Buy
Price Target: $240 → $241
Current: $166.87
Upside: +44.42%
Oct 13, 2026
Reiterated: Buy
Price Target: $34 → $33
Current: $14.73
Upside: +124.03%
Oct 7, 2026
Reiterated: Buy
Price Target: $286
Current: $239.77
Upside: +19.28%
Oct 7, 2026
Reiterated: Buy
Price Target: $87 → $85
Current: $26.80
Upside: +217.16%
Sep 22, 2026
Reiterated: Buy
Price Target: $155 → $151
Current: $83.61
Upside: +80.60%
Sep 15, 2026
Reiterated: Buy
Price Target: n/a
Current: $3.84
Upside: -
Sep 10, 2026
Reiterated: Buy
Price Target: n/a
Current: $84.78
Upside: -
Sep 1, 2026
Reiterated: Buy
Price Target: n/a
Current: $29.80
Upside: -
Aug 21, 2026
Reiterated: Buy
Price Target: n/a
Current: $13.29
Upside: -
Aug 18, 2026
Reiterated: Hold
Price Target: n/a
Current: $3.71
Upside: -
Jul 31, 2026
Reiterated: Hold
Price Target: $7
Current: $3.18
Upside: +120.13%
May 19, 2025
Reiterated: Buy
Price Target: $26
Current: $18.67
Upside: n/a
May 14, 2025
Reiterated: Buy
Price Target: $8
Current: $1.25
Upside: n/a
May 13, 2025
Reiterated: Hold
Price Target: $5
Current: $1.40
Upside: n/a
May 13, 2025
Reiterated: Hold
Price Target: $20
Current: $3.20
Upside: n/a
May 13, 2025
Reiterated: Buy
Price Target: $16
Current: $7.70
Upside: n/a
May 12, 2025
Reiterated: Buy
Price Target: $48 → $46
Current: $11.77
Upside: n/a
May 8, 2025
Reiterated: Hold
Price Target: $26
Current: $36.48
Upside: n/a
May 7, 2025
Reiterated: Buy
Price Target: $16
Current: $5.24
Upside: n/a
May 6, 2025
Reiterated: Buy
Price Target: $12 → $13
Current: $4.82
Upside: n/a
May 6, 2025
Reiterated: Hold
Price Target: $38
Current: $42.25
Upside: n/a
Jun 26, 2023
Downgraded: Hold
Price Target: $2,160 → $180
Current: $7.37
Upside: n/a
May 15, 2023
Reiterated: Hold
Price Target: $20.41
Current: $2.05
Upside: n/a
Mar 16, 2022
Reiterated: Hold
Price Target: $5 → $80
Current: $0.4063
Upside: n/a
Nov 12, 2021
Reiterated: Hold
Price Target: $1 → $15
Current: $0.000001
Upside: n/a
Sep 8, 2015
Rated: Buy
Price Target: $348
Current: $251.65
Upside: n/a